Related Experiment Video
Updated: Jun 4, 2026
06:51
Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy
Published on: December 17, 2019
Improving therapy for patients with aggressive lymphoma
1University of Nebraska Medical Center, 987680 Nebraska Medical Center, Omaha, NE 68198-7680, USA. joarmita@unmc.edu
Summary
Outcomes for diffuse large B-cell lymphoma have improved, but peripheral T-cell lymphoma requires further study. Future research will focus on subtype-specific treatments for both lymphoma types.
Area of Science:
- Hematology
- Oncology
- Immunology
Background:
- Outcomes for diffuse large B-cell lymphoma (DLBCL) have significantly improved over the past decade.
- Peripheral T-cell lymphoma (PTCL) remains a therapeutic challenge with limited targeted treatment options.
- Understanding disease heterogeneity is crucial for advancing lymphoma treatment.
Purpose of the Study:
- To highlight the need for subtype-specific therapeutic strategies in both DLBCL and PTCL.
- To emphasize the potential for personalized medicine in treating lymphoid malignancies.
- To outline future clinical investigation directions for improving patient outcomes.
Main Methods:
- Review of recent clinical outcomes and therapeutic advancements in lymphoma.
- Analysis of the current understanding of lymphoma subtypes and their distinct biological features.
- Identification of knowledge gaps in PTCL treatment and management.
Main Results:
- Dramatic improvements in DLBCL patient outcomes have been achieved.
- Significant opportunities exist to improve PTCL therapy through subtype-specific research.
- Genetic subtypes of both DLBCL and PTCL may necessitate distinct treatment approaches.
Conclusions:
- Personalized treatment strategies based on genetic subtypes are likely essential for both DLBCL and PTCL.
- Future clinical investigations should prioritize the study of specific lymphoma subtypes.
- Advancing the treatment of PTCL requires a deeper understanding of its diverse subtypes.
Related Concept Videos
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...